US DOL Final Rule PBM Disclosure: Mandates Transparency for Employers

• The U.S. Department of Labor's EBSA announced a final rule to regulate pharmacy benefit managers.
• PBMs and their affiliates must now disclose fees, compensation, manufacturer rebates, and payments recouped from pharmacies to self-insured employers.
• The rule specifically requires disclosure of compensation from "spread pricing" where the plan's cost exceeds the pharmacy's reimbursement.
• Self-insured employers gain the right to audit these disclosures and seek relief for PBM non-compliance.
• The DOL projects this rule will save health plans up to $22 billion in prescription drug costs over 10 years.

The U.S. Department of Labor anticipates that these comprehensive changes will lead to substantial financial benefits across the healthcare system, projecting that the final rule will reduce prescription drug costs for health plans by an estimated $22 billion over the next decade.

The U.S. Department of Labor's Employee Benefits Security Administration (EBSA) recently unveiled a significant final rule aimed at increasing transparency within the pharmacy benefit manager (PBM) industry. This new regulatory framework, announced on a Thursday, is designed to bring greater oversight to the operations of PBMs and their affiliated entities, a move that has garnered praise from various advocacy organizations. The core objective of this DOL final rule PBM disclosure is to empower self-insured employers with critical information regarding their prescription drug plans, fostering a more equitable and understandable healthcare landscape.

This EBSA PBM final rule specifically mandates that PBMs, along with any related companies, must provide detailed disclosures of their financial arrangements and compensation structures to the self-insured employers they serve. This includes a comprehensive breakdown of all fees collected and remuneration received, ensuring that every financial transaction is brought into the light. The new pharmacy benefit manager regulations represent a concerted effort to address long-standing concerns about the opaque nature of PBM financial practices, thereby ensuring that employers have a clearer, more complete picture of where their healthcare dollars are truly being allocated.

A central component of the new PBM fee disclosure requirements is the obligation for PBMs to reveal specific types of compensation that have historically been obscured. This encompasses rebates received directly from pharmaceutical manufacturers, which often play a substantial role in influencing the ultimate cost of prescription drugs. Additionally, PBMs must disclose any payments they recoup from pharmacies, shedding crucial light on another layer of their complex financial dealings. These mandated disclosures are crucial for self-insured employers seeking to understand the true cost components of their prescription drug benefits and to make more informed decisions.

Furthermore, the rule directly confronts the controversial practice of "spread pricing," where PBMs generate profit from the differential between what they charge a health plan for a drug and the amount they actually reimburse the dispensing pharmacy. Under these new regulations, PBMs are now explicitly required to disclose any compensation they receive in instances where the price paid by the health plan for a medication exceeds the amount paid out to the pharmacy. This particular aspect of the DOL prescription drug cost rule is specifically intended to curb practices that have historically inflated costs for health plans without providing corresponding benefits to either pharmacies or the patients they serve.

Beyond the new disclosure mandates, the DOL final rule PBM disclosure significantly enhances the rights and capabilities of self-insured employers. These employers are now explicitly granted the authority to audit the disclosures provided by PBMs, allowing them to independently verify the accuracy and completeness of the financial information presented. This robust right to conduct a self-insured employer PBM audit provides a crucial mechanism for accountability, enabling employers to actively monitor their PBMs' compliance with the new regulations and ensure fair practices.

Should a PBM fail to meet its responsibilities under these new rules, employers are entitled to seek additional relief, providing a clear recourse for non-compliance. This provision ensures that the disclosure requirements have genuine teeth and that PBMs are strongly incentivized to comply fully and transparently. The U.S. Department of Labor anticipates that these comprehensive changes will lead to substantial financial benefits across the healthcare system, projecting that the final rule will reduce prescription drug costs for health plans by an estimated $22 billion over the next decade. This significant projected saving underscores the profound potential impact of increased transparency and oversight in the PBM sector for both employers and beneficiaries.

Lawyers advising self-insured employers should inform clients of new PBM disclosure requirements and their right to audit PBM compensation to ensure compliance and potentially reduce prescription drug costs. Compliance officers at PBMs must update their disclosure protocols to meet the EBSA's new regulations.

Source: Original reporting via industry news.